Skip to main content

Table 8 Multivariable logistic regression analysis of the relationship between treatment types received by the patient and major depressive disorder

From: The psychological impact of inflammatory bowel disease as regards anxiety and depression: a single-center study

  Major depressive disorder OR (CI 95%) Test of significance
No (N = 46) Yes (N = 59)
N (%) N (%) Value p-value Sig.
Oral mesalamine No 14 (30.43%) 17 (28.81%) 1.08 (0.47–2.51) X2 = 0.033 0.857C NS
Yes 32 (69.57%) 42 (71.19%)
Topical mesalamine No 44 (95.65%) 57 (96.61%) 0.77 (0.11–5.7)   1.00F NS
Yes 2 (4.35%) 2 (3.39%)
Oral steroids No 28 (60.87%) 41 (69.49%) 0.68 (0.3–1.54) X2 = 0.853 0.356C NS
Yes 18 (39.13%) 18 (30.51%)
Topical steroids No 44 (95.65%) 59 (100%)    0.19F NS
Yes 2 (4.35%) 0 (0%)
Azathioprine No 16 (34.78%) 19 (32.2%) 1.12 (0.5–2.54) X2 = 0.077 0.781C NS
Yes 30 (65.22%) 40 (67.8%)
Biological therapy No 37 (80.43%) 47 (79.66%) 1.05 (0.4–2.76) X2 = 0.01 0.922C NS
Yes 9 (19.57%) 12 (20.34%)
Type remicade 1–Humera 2 No 40 (86.96%) 51 (86.44%) 1.05 (0.34–3.26) X2 = 0.006 0.939C NS
Yes 6 (13.04%) 8 (13.56%)
Surgical intervention No 43 (93.48%) 55 (93.22%) 1.04 (0.22–4.91)   1.00F NS
Yes 3 (6.52%) 4 (6.78%)
Did you stop TTT? No 40 (86.96%) 54 (91.53%) 0.62 (0.18–2.17)   0.529F NS
Yes 6 (13.04%) 5 (8.47%)
  1. CChi-square test of significance (X2, chi-square test value). FMonte-Carlo Fisher’s exact test of significance